New treatment strategies in non-responder patients with chronic hepatitis C

Journal of Hepatology, Supplement

Volumn 31, Issue 1, 1999, Pages 184-188

  Schalm, Solko W ^a   Brouwer, Johannes T ^a   Bekkering, Frank C ^a   Van Rossum, Tekla G J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Chronic hepatitis C; Combination therapy; Hepatitis C virus; Hepatitis C virus RNA; Interferon; Ribavirin; Therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; AMANTADINE; GLYCYRRHIZIC ACID; RIBAVIRIN; URSODEOXYCHOLIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CONFERENCE PAPER; DISEASE SEVERITY; DRUG EFFICACY; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETREATMENT; TREATMENT OUTCOME; VIRUS LOAD;

EID: 0033452827     PISSN: 01695185     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(99)80398-5     Document Type: Conference Paper

References (32)

1. Craxi A, Almasio P, Schalm SW. Evaluation of efficacy of antiviral therapy for chronic hepatitis C: a Eurohep consensus report on response criteria. J Viral Hepat 1996: 3: 273-276.
2. Tong MJ, Blatt LM, McHutchison JG, Co RL, Conrad A. Prediction of response during Interferon alpha 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997: 26: 1640-1645.
3. Davis GL, Baiart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP et al. Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized, controlled trial. N Engl J Med 1989: 321: 1501-1506.
4. Brouwer JT, Nevens F, Kleter B, Elewaut A, Adler M, Brenard R et al. Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients. J Hepatol 1998: 28: 951-959.
5. Marcellin P, Boyer N, Gervais A, Martinet M, Pouteau M, Castelman C et al. Long-term histologie improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997: 127: 875-881.
6. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997: 112: 463172.
7. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997: 79: 1494-500.
8. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998: 27: 1394-1402.
9. Mathurin P, Moussalli J, Cadranel JF, Thibault V, Charlotte F, Dumouchel P et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998: 27: 868-872.
10. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998: 339(2): 61-68.
11. Poynard T, Bedossa P, Chavallier M, Mathurin P, Lemonnier C, Trepo C et al. A comparison of three interferon alpha-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995: 332: 1457-462.
12. Alberti A, Chemello L, Noventa F, Cavalletto L, Salvo GL de. Therapy of hepatitis C: re-treatment with alpha interferon. Hepatology 1997: 26(Suppl 1): 137S-142S.
13. Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O et al. Ribavirin enhances the efficacy but not the adverse effects of Interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol 1997: 26: 961-966.
14. Heathcote EJL, Keeffe EB, Lee SS, Feinman SV, long MJ, Reddy KR et al. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology 1998: 27: 1136-1143.
15. Bekkering FC, Brouwer JT, Leroux-Roels G, Vlierberghe H van, Elewaut A, Schalm SW. Ultrarapid hepatitis C virus clearance by daily high dose interferon in non-responders to standard therapy. J Hepatol 1998: 28: 960-964.
16. Bekkering FC, Brouwer JT, Elewaut A, Schalm SW. Hepatitis C: viral kinetics. Hepatology 1997: 26: 1691-1692.
17. McCarthy ME, Ganger D, Flamm S, Lam NP, Wiley TE, Layden TJ. Early viral response to high dose interferon a-2B (IFN) predicts viral response in prior non-responders (NR) and relapsers (R) to IFN. Hepatology 1998: 28 (Suppl): 287A.
18. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alpha. Hepatology 1997: 26: 226231.
19. Brouwer JT, Nevens F, Michielsen P, Hautekeete ML, Chamuleau RAFM, Adler M et al. What options are left when hepatitis C does not respond to interferon? Placebo controlled Benelux multicentre retreatment trial on ribavirin monotherapy versus combination with interferon. J Hepatol 1994: 21(Suppl 1): S17.
20. Smith JP. Treatment of chronic hepatitis C with amantadine. Dig Dis Sei 1997: 42: 1681-7.
21. El-Zayadi A, Selim O, Shawky S, Moustafa H, El-Taweel A. A controlled study of amantadine monotherapy vs. amantadine combined with interferon-a in chronic hepatitis C patient nonresponders to interferon-a. Hepatology 1998: 28: 473A.
22. Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C et al. A pilot study of combination therapy with ribavirin plus interferon alpha for alpha-interferon resistant chronic hepatitis C. Gastroenterology 1994: 107: 812-817.
23. Sostegni R, Ghisetti V, Pittaluga F, Marchiaro G, Rocca G, Borghesio E et al. Sequential versus concomitant administration of ribavirin and Interferon alpha-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial. In press.
24. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G et al. Randomised trial of interferon a2b plus ribavirin for 48 weeks or for 24 weeks versus interferon c2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998: 352: 1426-1432.
25. McHutchison JG, Gordon SC, Schiff ER, Shiftman ML, Lee WM, Rustgi VK et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998: 339: 1485-1492.
26. Bekkering FC, Brouwer JT, Niesters HGM, Siebelink CHJ, Schalm SV. Viral kinetics of the hepatitis C virus in patients treated with hish dose daily combination therapy. Hepatology 1998: 28 (Suppi): 288A.
27. Younossi ZM, Müllen KD, Zakko W, Brandt E, Hodnick S, Easley K et al.-Interferon a2b and ribavirin vs interferon a2b and amantadine for chronic hepatitis C (non-responder): a multicenter, randomized, double-blind trial. Hepatology 1998: 28: 284A.
28. Brillant! S, Foli M, Gramantieri L, Di Tomaso M, Masci C, Bolondi L. Triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders: a pilot randomized controlled study. Hepatology 1997: 26: 367A.
29. Rossum TGJ van, Vulto AG, Hop WCJ, Brouwer JT, Schalm SW. Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind placebo-controlled randomized trial. Hepatology 1998: 28: 573A.
30. Takano S, Ito Y, Yokosuka O, Ohio M, Uchiumi K, Hirota K et al. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 1994: 20: 558-564.
31. Hoofnagle JH, Lau D, Conjeevaram H, Kleiner D, Di Bisceglie AM. Prolonged therapy of chronic hepatitis C with ribavirin. J Viral Hepat 1996: 3: 247-252.
32. Hino L, Miyakawa H, Takahashi J, Kumada H, Ikeda K, Yoshiba A et al. Effect of large dose of SNMC on the liver histology of chronic active hepatitis (in Japanese). Kan-Tansui 1986: 13: 797.